Cipla receives final approval for generic version of Eli Lilly Cos Adcirca Kumar Jeetendra | February 7, 2019 Mumbai, India, February 7, 2019: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg from the United States Food and Drug Administration (US FDA). Cipla’s Tadalafil Tablets 20mg is AB-rated generic therapeutic …
Cole Parmer launches its biggest Pharma Resource Book Dedicated to Pharma and Biopharma customers needs from research to production Kumar Jeetendra | February 12, 2019 Cole-Parmer, a leading manufacturer and supplier of laboratory and industrial products, instrumentation, and supplies recently launched its biggest Pharma Resource Book 2019-20, dedicated to meet application needs of Pharmaceutical and Biopharma customers. For biopharma product development, the pharma resource book addresses the pain areas of the customers such as compliance, SOP concerns, customized solutions, validation …
Dr Reddys Laboratories launches Tadalafil Tablets USP in the US Market Kumar Jeetendra | February 12, 2019 Hyderabad, India and Princeton, NJ, USA. February 12,2019—Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch ofTadalafil Tablets USP, a therapeutic equivalent generic version of Adcirca (tadalafil) Tabletsin the United States market, approved by the U.S. Food and Drug Administration …
Cipla and Wellthy Therapeutics Announce Partnership to offer Digital Therapeutics for Diabetes and Cardiovascular Diseases Kumar Jeetendra | February 25, 2019 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) and Wellthy Therapeutics Private Limited (“Wellthy Therapeutics”) today announced that they have entered into a partnership to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of diabetology and cardiology. Under the agreement, a multi-lingual …